APTN-101 Phase 1 Initiates Against a Validated Failure: BBB Delivery, Not Biology, Is the Swing Factor

Adaptin Bio Opens Enrolment for Phase I Glioblastoma Trial

Adaptin Bio has initiated enrolment for a Phase I clinical trial of its Brain Bispecific T cell Engager (BRiTE) therapy, APTN-101, for adults with glioblastoma. This first-in-human, open-label, dose-escalation study, conducted in partnership with Duke University in the US, aims to determine the safety profile and maximum tolerated dose of APTN-101 in up to 15 patients diagnosed with WHO Grade IV Malignant Glioma. The BRiTE platform is designed to improve drug delivery across the blood-brain barrier and specifically target tumour cells expressing the epidermal growth factor receptor variant III (EGFRvIII). The US FDA granted IND clearance in September 2024, paving the way for this trial.

• The Phase I trial is an open-label, dose-escalation study being conducted in collaboration with Duke University in the US. It is designed to enroll up to 15 adult patients diagnosed with World Health Organization (WHO) Grade IV Malignant Glioma. The primary objective is to establish the safety profile and determine the maximum tolerated dose of APTN-101, marking a crucial step in its clinical development.
• APTN-101 leverages Adaptin Bio's proprietary BRiTE technology, engineered to enhance drug delivery across the blood-brain barrier. This innovative platform specifically targets and attacks glioma tumour cells that express the epidermal growth factor receptor variant III (EGFRvIII). Preclinical studies demonstrated impressive efficacy, including the elimination of some malignant glioma tumours across multiple aggressive disease models, suggesting its potential as a best-in-class therapy.
• The trial's primary endpoint focuses on the proportion of patients experiencing dose-limiting toxicity at each dose level. Secondary endpoints include the analysis of APTN-101 pharmacokinetics and objective response rate, measured by modified Response Assessment in Neuro-Oncology Criteria. Exploratory objectives will assess biological activity, anti-BRiTE antibody development, overall survival, and progression-free survival. The US FDA granted Investigational New Drug (IND) application clearance in September 2024, enabling the commencement of this Phase I study.

Addressing the Persistent Challenges in Glioblastoma Treatment

Glioblastoma (GBM) remains one of the most treatment-refractory malignancies in oncology, with median survival largely unchanged despite decades of therapeutic advancement. Multiple intersecting biological and pharmacological barriers undermine the efficacy of current standard-of-care and emerging approaches.

• Blood-Brain Barrier (BBB) Drug Penetration: The BBB constrains systemic chemotherapy delivery, particularly at the tumor periphery where infiltrating cells reside within regions of intact barrier function. Even where focal BBB disruption occurs in the tumor core, therapeutic drug concentrations remain insufficient across the broader infiltrative zone, directly limiting treatment efficacy.

• Surgical Incompleteness: Radical surgical ablation is anatomically and functionally precluded in the brain. Even minimal residual tumor burden is sufficient to drive rapid recurrence, and complete tumor eradication — a prerequisite for cure — remains unachievable with current resection techniques.

• Temozolomide Resistance: TMZ efficacy is contingent on intact DNA mismatch repair (MMR) machinery and is intrinsically limited by O6-methylguanine-DNA methyltransferase (MGMT)-mediated resistance. Although MGMT promoter methylation occurs in approximately 45% of cases, TMZ confers no survival benefit in the first nine months post-treatment in unselected populations. Acquired resistance through MMR mutation drives aggressive tumor regrowth following initial response, and additional uncharacterized resistance mechanisms — including decoupling of the DNA damage response from ongoing genotoxic insult — further erode therapeutic durability.

• Glioblastoma Stem Cells (GSCs): GSCs exhibit robust tumorigenic and invasive capacity underpinned by enhanced DNA repair, distinct molecular signatures, and metabolic adaptations that confer resistance to both chemotherapy and radiotherapy. Their persistence following treatment is widely implicated in the near-universal pattern of tumor recurrence.

• Immunosuppressive Tumor Microenvironment: GBM harbors an inherently "cold" tumor immune microenvironment (TIME), characterized by a high ratio of pro-tumor to anti-tumor immune infiltrates and spatiotemporally dynamic immunosuppressive cell-cell interactions. This microenvironmental architecture has rendered immunotherapy — despite its success across other solid tumor indications — largely ineffective in GBM clinical trials to date.

• Intratumoral Heterogeneity: GBM demonstrates profound cellular and tissue heterogeneity, supported by a remodeled extracellular scaffold with altered composition and mechanical properties that actively facilitates tumor cell infiltration and migration. This heterogeneity complicates therapeutic targeting and contributes to the emergence of treatment-resistant subclonal populations.

APTN-101's BRiTE Platform: An Emerging Mechanism for Glioblastoma

Glioblastoma and malignant glioma research has seen a meaningful shift toward mechanistically diverse therapeutic strategies over the past three years, moving well beyond conventional cytotoxic approaches. Emerging mechanisms span immunological, metabolic, and combination paradigms, each addressing distinct vulnerabilities of the tumor microenvironment and tumor cell biology.

• CAR T Cell Therapy with Multiantigen Targeting: CAR T cell constructs directed against tumor-associated antigens — including IL-13Rα2, HER2, EGFR, EGFRvIII, EphA2, GD2, and B7-H3 — represent an advancing front in GBM immunotherapy. Recent innovations focus on multiantigen targeting strategies, alternative cell sourcing, and optimized delivery routes to counteract key resistance mechanisms such as antigen downregulation and limited CAR T cell persistence within the immunosuppressive tumor microenvironment.

• Bispecific T Cell Engagers (BTEs) Targeting IL13RA2: Fully humanized BTEs bridge T cells to GBM tumor cells via IL13RA2 in an MHC-independent manner, enabling cytotoxic activity that bypasses classical antigen presentation constraints. In vivo xenograft models of both primary and recurrent GBM demonstrated robust target-specific activity and markedly prolonged survival, with no detectable off-target local or systemic toxicity.

• Dendritic Cell (DC) Vaccination: Meta-analytic data indicate that DC vaccination combined with standard of care is associated with significantly improved overall survival (HR = 0.71; 95% CI, 0.57–0.88) and progression-free survival (HR = 0.65; 95% CI, 0.43–0.98). In newly diagnosed GBM specifically, DC vaccination was associated with improved PFS (HR = 0.59; 95% CI, 0.39–0.90), with trial sequential analysis confirming the cumulative z-score crossed the benefit boundary at the required sample size threshold.

• Immune Checkpoint Inhibition Informed by IDH Mutation Status: High expression of PDCD1 and CD274 has been observed irrespective of IDH1 mutation status, suggesting broad applicability of checkpoint blockade across GBM molecular subtypes. IDH1-wild-type glioblastomas may require co-targeting of the PI3K/AKT/mTOR axis alongside checkpoint inhibition, given PIK3R1 overexpression in this subgroup.

• Metabolic Subtyping of Tumor-Associated Macrophages (TAMs): Glioma-associated macrophages have been reclassified into four metabolic subtypes — Glycolipid-Signaling (GSM), Detoxification and Energic (DEM), Polymetabolic (PmM), and Glycolipid Metabolism/Immunoregulatory (GMIM). The DEM subtype, characterized by terminal differentiation and enrichment in detoxification and energy pathways, correlates significantly with advanced tumor grade and poor survival (p < 0.05). Six core prognostic markers — CLIC1, FABP5, FCER1G, S100A8, S100A9, and SPP1 — have been identified within this framework.

• ROS-Mediated Radioresistance via RNF7: RNF7 exerts a buffering effect against radiation-induced oxidative stress and counterbalances redox stress associated with IDH1 mutation through anti-ROS activity. Elevated RNF7 expression is associated with heightened metabolic resilience in glioma cells, contributing to radiotherapy resistance and representing a potential therapeutic target.

• Clofazimine as an Immunotherapy and Chemotherapy Potentiator: Clofazimine has demonstrated enhancement of cytotoxic activity when combined with temozolomide, paclitaxel, and carboplatin. In experimental models, combining dendritic cell vaccine with clofazimine and chemoradiation extended median survival to 90 ± 7 days versus 45 ± 5 days in controls. This regimen was associated with a stronger anti-tumor immune response, evidenced by elevated serum interleukin-1β and IL-18 levels, and increased IBA1⁺/CD68⁺ pro-inflammatory microglial infiltration within neoplastic tissue.

Unpacking the Phase I Trial Design for APTN-101 in Glioblastoma

The clinical development landscape for glioblastoma (GBM) and malignant glioma spans a range of trial designs, from single-arm Phase I/II dose-escalation studies to retrospective cohorts and systematic meta-analyses. Across both newly diagnosed and recurrent settings, progression-free survival (PFS) and overall survival (OS) dominate as primary and secondary endpoints, with response assessments predominantly conducted using RANO criteria. The following table summarizes key trial parameters and outcomes across the major studies identified in the literature.

A Novel Bispecific Engager Targets Glioblastoma's Toughest Barriers

Glioblastoma (GBM) remains one of oncology's most formidable challenges, characterized by its aggressive nature, rapid progression, and a dismal prognosis that has seen little improvement in decades. Current treatment modalities often fall short, primarily due to their non-specific action and the brain's natural defenses, particularly the blood-brain barrier (BBB), which severely restricts drug delivery to the tumor site. This dire unmet need underscores the significance of Adaptin Bio's move to initiate a Phase I clinical trial for APTN-101, a novel Brain Bispecific T cell Engager (BRiTE) therapy.

APTN-101 represents a promising new frontier in GBM immunotherapy. By specifically targeting the epidermal growth factor receptor variant III (EGFRvIII), an antigen found exclusively on tumor cells, this therapy aims to redirect the immune system with exquisite precision, minimizing damage to healthy tissue. The BRiTE platform's innovative design to enhance BBB penetration is a critical strategic advantage, addressing a fundamental hurdle that has stymied many previous therapeutic attempts. This first-in-human study, conducted in collaboration with Duke University, a recognized leader in neuro-oncology research, is a crucial step in validating the safety and initial tolerability of this approach.

However, the path forward is not without its complexities. While bispecific T-cell engagers offer potent anti-tumor activity, they also carry the risk of immune-related toxicities, such as cytokine release syndrome, which will be closely monitored during dose escalation. Furthermore, the inherent heterogeneity of GBM tumors and the potential for antigen escape mechanisms mean that even highly specific therapies may face challenges in achieving durable responses. Ensuring that APTN-101 can not only cross the BBB but also maintain its functional activity within the unique microenvironment of the brain will be paramount. This trial, therefore, is not just about a new drug; it's about testing a novel paradigm for overcoming some of the most persistent obstacles in treating one of the deadliest cancers.